AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03983720 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: * Fatigue Severity Scale (FSS)~* Modified Fatigue Impact Scale (MFIS)~* Godin Leisure-Time Exercise Questionnaire (GLTEQ)~* Scale of life quality of multiple sclerosis (SEP-59)~* Center for Epidemiologic Studies Depression (CES-D)~* Pittsburgh Sleep Quality Index (PSQ-I)
Study NCT03983720 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: * Fatigue Severity Scale (FSS)~* Modified Fatigue Impact Scale (MFIS)~* Godin Leisure-Time Exercise Questionnaire (GLTEQ)~* Scale of life quality of multiple sclerosis (SEP-59)~* Center for Epidemiologic Studies Depression (CES-D)~* Pittsburgh Sleep Quality Index (PSQ-I)
Study NCT03983720 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample
Description: Blood sample will be realized to evaluate anemia and inflammations.
Study NCT03983720 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood sample will be realized to evaluate anemia and inflammations.
Study NCT03983720 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiopulmonary evaluation
Description: Cardiopulmonary evaluation will be realized with a cycle ergometer.
Study NCT03983720 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary evaluation
Description: Cardiopulmonary evaluation will be realized with a cycle ergometer.
Study NCT03983720 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Capacity of muscular oxygen extraction
Description: Measure the capacity of muscular oxygen extraction with a cycle ergometer.
Study NCT03983720 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Capacity of muscular oxygen extraction
Description: Measure the capacity of muscular oxygen extraction with a cycle ergometer.
Study NCT03983720 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sleep assessment
Description: Sleep assessment will be measured by actigraphy during 15 days.
Study NCT03983720 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sleep assessment
Description: Sleep assessment will be measured by actigraphy during 15 days.
Study NCT03983720 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Metabolic fatigue
Description: Metabolic fatigue will be measured by Magnetic Resonance Imaging (MRI).
Study NCT03983720 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Metabolic fatigue
Description: Metabolic fatigue will be measured by Magnetic Resonance Imaging (MRI).
Study NCT03983720 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular evaluation
Description: Neuromuscular evaluation will be measured by the composite of the results of:~* Fatigue test~* Measure of voluntary isometric force~* Surface electromyography~* Peripheral nerve stimulation~* Transcranial Magnetic Stimulation (TMS)~* Perceived fatigue~* Cognitive fatigue~* Thermoregulation
Study NCT03983720 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular evaluation
Description: Neuromuscular evaluation will be measured by the composite of the results of:~* Fatigue test~* Measure of voluntary isometric force~* Surface electromyography~* Peripheral nerve stimulation~* Transcranial Magnetic Stimulation (TMS)~* Perceived fatigue~* Cognitive fatigue~* Thermoregulation
Study NCT03890900 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: T2DXcel mobile application
Description: T2DXcel is a mobile application (patient-facing) that delivers guideline-based diabetes education.
Study NCT01813201 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone undecanoate
Description: Testosterone undecanoate intramuscular long-acting, 1000 mg/dose, administered at inclusion and every 12 weeks for 9 months (4 dose) (testosterone group) against the administration of placebo (saline isotonic solution).
Study NCT01813201 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline isotonic solution
Description: Saline isotonic solution (placebo)intramuscular,administered at inclusion and every 12 weeks for 9 months (4 dose)
Study NCT03019523 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine Blend
Description: Taken orally in capsule form
Study NCT03019523 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: Taken orally in capsule form
Study NCT00654225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Study NCT00654225 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Study NCT02679781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nasal midazolam
Description: administration of 0.2mg/kg nasal midazolam. During dental treatment 50% nitrous oxide/ 50% oxygen will be administered via nasal hood.
Study NCT05199883 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TI.VA algorithm: decision support system
Description: TI.VA algorithm uses BIS and MAP values as control variables to suggest the intervention on propofol and remifentanil levels.
Study NCT00545467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Aripiprazole will be given as a fixed does, 15 mg/day, orally throughout 8 weeks in the 2 arms.
Study NCT04980586 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CASA score protocol to Non-obstructive sleep apnea Group
Description: CASA score observe the cheeks appearance: volume of the cheeks (0, 1, 2 or 3) and flaccidity, (0, 1, 2 or 3). The final score is volume + flaccidity score to have the CASA score (0-6). A photography was captured to enable the blinded evaluation of three evaluators of each participant. Ultrasonography was positioned in the face of the participant and slide to capture the muscle image (masseter muscle, buccinator and the tongue). Tongue and cheeks pressure were assessed with a device with a small bulb. Inside the mouth in the tongue, the participant is instructed to press the bulb against the hard palate. In the cheeks, the bulb is placed between the cheek and the teeth and the participant press the bulb with the cheek. Swallowing evaluation with an endoscope that enters in the nose of the participant to observe the the oropharynx; while the participant is eating liquid consistency, pureed consistency and solid food.
Study NCT04980586 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CASA score protocol to Mild obstructive sleep apnea Group
Description: CASA score observe the cheeks appearance: volume of the cheeks (0, 1, 2 or 3) and flaccidity, (0, 1, 2 or 3). The final score is volume + flaccidity score to have the CASA score (0-6). A photography was captured to enable the blinded evaluation of three evaluators of each participant. Ultrasonography was positioned in the face of the participant and slide to capture the muscle image (masseter muscle, buccinator and the tongue). Tongue and cheeks pressure were assessed with a device with a small bulb. Inside the mouth in the tongue, the participant is instructed to press the bulb against the hard palate. In the cheeks, the bulb is placed between the cheek and the teeth and the participant press the bulb with the cheek. Swallowing evaluation with an endoscope that enters in the nose of the participant to observe the the oropharynx; while the participant is eating liquid consistency, pureed consistency and solid food.
Study NCT04980586 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CASA score protocol to Moderate obstructive sleep apnea Group
Description: CASA score observe the cheeks appearance: volume of the cheeks (0, 1, 2 or 3) and flaccidity, (0, 1, 2 or 3). The final score is volume + flaccidity score to have the CASA score (0-6). A photography was captured to enable the blinded evaluation of three evaluators of each participant. Ultrasonography was positioned in the face of the participant and slide to capture the muscle image (masseter muscle, buccinator and the tongue). Tongue and cheeks pressure were assessed with a device with a small bulb. Inside the mouth in the tongue, the participant is instructed to press the bulb against the hard palate. In the cheeks, the bulb is placed between the cheek and the teeth and the participant press the bulb with the cheek. Swallowing evaluation with an endoscope that enters in the nose of the participant to observe the the oropharynx; while the participant is eating liquid consistency, pureed consistency and solid food.
Study NCT04980586 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CASA score protocol to Severe obstructive sleep apnea Group
Description: CASA score observe the cheeks appearance: volume of the cheeks (0, 1, 2 or 3) and flaccidity, (0, 1, 2 or 3). The final score is volume + flaccidity score to have the CASA score (0-6). A photography was captured to enable the blinded evaluation of three evaluators of each participant. Ultrasonography was positioned in the face of the participant and slide to capture the muscle image (masseter muscle, buccinator and the tongue). Tongue and cheeks pressure were assessed with a device with a small bulb. Inside the mouth in the tongue, the participant is instructed to press the bulb against the hard palate. In the cheeks, the bulb is placed between the cheek and the teeth and the participant press the bulb with the cheek. Swallowing evaluation with an endoscope that enters in the nose of the participant to observe the the oropharynx; while the participant is eating liquid consistency, pureed consistency and solid food.
Study NCT04077489 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: cataract surgery
Description: To measure the MT in congenital cataracts before and after the cataract extraction with IOL implantation surgery
Study NCT00008411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Every 3 weeks at a starting dose of 75 mg/m2 IV over 1 hour on day 1, repeated every 21 days.
Study NCT00008411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 35 mg/m2 IV over 30 minutes on days 1, 8, and 15, for 3 weeks followed by one week of rest repeated every 28 days.
Study NCT04202068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftriaxone sodium and Sulbactam Sodium for injection
Description: Ceftriaxone sodium and Sulbactam Sodium for injection is available as sterile powder for reconstitution.It will be administered as one 3g IV dose for adult or one 75mg/kg IV dose for children under 12.
Study NCT00428935 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAAV2.5-CMV-minidystrophin (d3990)
Description: Recombinant adeno-associated virus (AAV) carrying a truncated human dystrophin gene (mini-dystrophin) expressed from a cytomegalovirus (CMV) promoter.
Study NCT01013324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL147 (SAR245408)
Description: dosed as capsules taken orally daily
Study NCT01453972 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Long distanse moderate training
Description: Moderate exercise
Study NCT01453972 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Long interval training
Description: High-intensity exercise, long duration
Study NCT01453972 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short interval training
Description: High intensity exercise, short duration
Study NCT00187538 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary
Description: dietary
Study NCT03715881 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Erythropoietin injection
Description: 1000 units of erythropoietin every 12 hours for three days
Study NCT01480726 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery
Study NCT00868543 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic gastric Roux-en-Y gastric bypass
Description: The fundus is separated by linear cutter. The intestine is opened approximately 75 cm from the ligament of Treitz and approached to the stomach. The gastrojejunostomy is performed in antecolic position The jejunum has to be in an antimesenteric position. After removing the endocutter, the anastomotic incision is closed with a continuous suture. The distance between the gastrojejunostomy and jejunojejunostomy was measured on the antimesenteric border with the bowel on a stretch. The jejunojejunostomy is performed in 150cm distance from gastrojejunostomy. The anastomosis is made by a posterior staple line and an anterior suture line. Preparation of a small window for the endocutter branches into the jejunal mesenterium 2-3 cm proximal to the gastrojejunostomy and above the entero-intestinal anastomosis.
Study NCT00868543 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic gastric Roux-en-Y gastric bypass
Description: The fundus is separated by linear cutter. The intestine is opened approximately 75 cm from the ligament of Treitz and approached to the stomach. The gastrojejunostomy is performed in antecolic position The jejunum has to be in an antimesenteric position. After removing the endocutter, the anastomotic incision is closed with a continuous suture. The distance between the gastrojejunostomy and jejunojejunostomy was measured on the antimesenteric border with the bowel on a stretch. The jejunojejunostomy is performed in 250cm distance from gastrojejunostomy. The anastomosis is made by a posterior staple line and an anterior suture line. Preparation of a small window for the endocutter branches into the jejunal mesenterium 2-3 cm proximal to the gastrojejunostomy and above the entero-intestinal anastomosis.
Study NCT00639678 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 40 mg/kg intravenously, double dose (day 0 and 14), Group 3
Study NCT03767998 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory muscle training for IMST
Description: 2 sets of 30 breaths or 6 sets of 10 repetitions with one or two minute of rest between sets, once per day, 5 days per week, training with breathing trainer.
Study NCT01232127 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Atazanavir
Description: Capsule, oral, 300 mg, once daily, 10 days
Study NCT03767998 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular Rehabilitation
Description: Regular Rehabilitation: 2-3 times a week, 6 weeks.
Study NCT01232127 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Atazanavir
Description: Capsule, oral, 400 mg, once daily, 7 days
Study NCT01232127 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ritonavir
Description: Capsule, oral, 100 mg, once daily, 10 days
Study NCT03767998 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular Rehabilitation
Description: Regular Rehabilitation: 2-3 times a week, 6 weeks.
Study NCT00639678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raxibacumab
Description: 40 mg/kg intravenously, double dose (day 0 and 14), Group 1
Study NCT00639678 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 40 mg/kg placebo, single dose (day 0), Group 4
Study NCT00639678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raxibacumab
Description: 40 mg/kg intravenously, single dose, day 0, Group 2
Study NCT00936559 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMP-655/ACS or Standard of Care
Description: Decision was made by Legal to withhold this information
Study NCT00936559 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMP-655/ACS or Standard of Care
Description: Decision was made by Legal to withhold this information.
Study NCT00936559 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMP-655/ACS or Standard of Care
Description: Decision was made by Legal to withhold this information,
Study NCT01524471 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Per Oral Endoscopic Myotomy
Study NCT00681083 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heated breathing tube (CPAP with ThermoSmart)
Description: CPAP with ThermoSmart - heated passover humidifier, with heated breathing tube
Study NCT00681083 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non heated breathing tube (CPAP with conventional humidification)
Description: CPAP with conventional humidification - heated passover humidifier, no heated breathing tube
Study NCT01178957 — intervention group
Intervention type: OTHER
Intervention: Hyperglycemia
Description: Hyperglycemia with a blood glucose of 15 mmol/L
Study NCT02356575 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Study NCT02356575 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavior Therapy
Study NCT03414060 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Menstrual Cup
Study NCT02160535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Description: 155 units of OnabotulinumtoxinA administered intramuscularly. Injections are divided across seven injection specific head/neck muscle areas every 12 weeks to prevent chronic migraine post traumatic headache
Study NCT02530060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine FDC
Description: Fixed dose combination tablet contains 25 milligram (mg) of Rilpivirine, 300 mg of Tenofovir Disoproxil Fumarate (TDF) and 200 mg of Emtricitabine (FTC).
Study NCT01501175 — intervention group
Intervention type: OTHER
Intervention: consultation with a vascular physician
Description: As in usual practice, patient with suspected SVT will consult a vascular physician to diagnose SVT and eventually DVP/PE associated. Vascular physician will collect risk factors of SVT.
Study NCT02370134 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Parkinson's glove
Description: Parkinson's glove had module for detection tremor by gyroscope/acceleroscope and suppression rest hand tremor with electrical muscle stimulation
Study NCT02370134 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham glove
Study NCT01227434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0332991 (pre-surgery)
Description: PD 0332991 for 7 days prior to an indicated, intended surgical resection for progression
Study NCT01227434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0332991
Description: PD 0332991 daily for 21 consecutive days followed by a 7 day break off therapy, repeating cycles
Study NCT01227434 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection as clinical care
Description: Indicated, intended, surgical resection as clinical care
Study NCT04455113 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Phosphorus level
Description: infusion
Study NCT04002713 — intervention group
Intervention type: OTHER
Intervention: ALT flap reconstruction
Description: Patients who underwent ALT free flap reconstruction after head and neck cancer surgery.
Study NCT04002713 — intervention group
Intervention type: OTHER
Intervention: AMT flap reconstruction
Description: Patients who underwent AMT free flap reconstruction after head and neck cancer surgery.
Study NCT02126020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical infliximab
Description: topical infliximab administered QID for 3 months followed by BID for 9 months
Study NCT03486223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2256294
Description: Drug will be taken daily by mouth for 7 days.
Study NCT03486223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsule
Description: Placebo will be taken daily by mouth for 7 days.
Study NCT04365296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: The purpose of the study is to evaluate which is more effective aerobic or resistance exercises in reducing plasma liver enzymes level (AST and ALT) post burn. Subjects and Methods: Sixty burned patients with burned body surface area about 30% to 50% will participate in this study. Their ages will be ranged from 20-45 years. They will be selected from Orabi Hospital and will be divided randomly into two equal groups.
Study NCT01996852 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral Meetings
Description: The cognitive-behavioral intervention will consist of six monthly in-person meetings and five telephone follow-ups. In-person meetings include a 90-minute educational group session and five 60-minute therapeutic couple-based meetings which partners are asked to attend. The telephone follow-ups last 15-30 minutes and take place two weeks after each in-person meeting. They will review progress and provide support.~Each monthly meeting has a focused topic: Introduction, Guided imagery, Sensate focus, Communication and relationship issues, and Review.~Homework will be assigned at the end of each meeting. Generally, participants are instructed (a) practice guided imagery daily, (b) engage in sexual activity 1-2 times/ week after sildenafil intake and (c) use the pump every day for 10min.
Study NCT01996852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sildenafil citrate
Description: 100mg of sildenafil citrate will be given twice a week to interested patients. Participants may start Sildenafil at a lower dose when needed.~To increase external validity, participants will be given the choice of using Sildenafil in the study.
Study NCT01996852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil citrate
Description: 100mg of sildenafil citrate will be given twice a week to interested patients. Participants may start Sildenafil at a lower dose when needed.~To increase external validity, participants will be given the choice of using Sildenafil in the study.